Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 221,990,859 papers from all fields of science
Search
Sign In
Create Free Account
EMD 72000
Known as:
EMD-72000
, EMD72000
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
matuzumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
MR Signal Amplification for Imaging of the Mutant EGF Receptor in Orthotopic Human Glioma Model
M. Shazeeb
,
Suresh Gupta
,
A. Bogdanov
Molecular Imaging and Biology
2013
Corpus ID: 20520809
PurposeTo investigate the potential of targeted MR signal amplification strategy for imaging of EGF receptor variant III…
Expand
2011
2011
MR Imaging of U 87 Δ EGFR Human Glioma Tumor Xenografts Using Targeted Signal-Amplifying Enzymatic System
M. Shazeeb
,
Suresh Gupta
,
Alexei A. Bogdanov
2011
Corpus ID: 264727041
Introduction: A truncated and constitutively active form of the EGF receptor variant III (EGFRvIII) is a major determinant of…
Expand
2006
2006
Signifikante EGF Rezeptor Inhibition und anhaltende antineoplastische Wirkung durch Matuzumab Kurzzeittherapie (EMD72000) im experimentellen Pankreaskarzinom Matuzumab short term therapy (EMD72000…
A. Kleespies
,
O. Mantell
,
C. Amendt
,
M. Yezhelyev
,
M. Guba
,
C. Bruns
2006
Corpus ID: 75539670
Pancreatic cancer continues to be a major unsolved health problem with a median overall survival of 4-6 month. Standard…
Expand
Review
2005
Review
2005
Monoclonal antibodies targeting the epidermal growth factor receptor.
Roberto Bianco
,
G. Daniele
,
F. Ciardiello
,
G. Tortora
Current Drug Targets
2005
Corpus ID: 25839054
The epidermal growth factor receptor (EGFR, HER1) autocrine pathway contributes to a number of highly relevant processes in…
Expand
2005
2005
Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth
C. Bangard
,
A. Gossmann
,
A. Papyan
,
Samir Tawadros
,
M. Hellmich
,
C. Bruns
International Journal of Cancer
2005
Corpus ID: 926696
The purpose of our research was to investigate the antiangiogenic effect of the epidermal growth factor receptor monoclonal…
Expand
2005
2005
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies
M. Seiden
,
H. Burris
,
+6 authors
F. Muggia
2005
Corpus ID: 75663232
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and…
Expand
2005
2005
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK…
T. Doi
,
A. Ohtsu
,
+7 authors
F. Rojo
2005
Corpus ID: 79216533
3077 Background: Matuzumab is a humanized monoclonal antibody binding to the EGFR with higher affinity than natural ligands (eg…
Expand
2004
2004
Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer.
U. Graeven
,
I. Vogel
,
+7 authors
W. Schmiegel
Journal of Clinical Oncology
2004
Corpus ID: 1843963
3061 Background: Monoclonal antibody EMD 72000 blocks ligand binding and inhibits EGFR activation and signal transduction. EGFR…
Expand
2004
2004
Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC).
J. Hoffend
,
A. Mohammed
,
+7 authors
U. Haberkorn
Journal of Clinical Oncology
2004
Corpus ID: 24541361
3043 Background: EGFR is a potential therapeutic target in HNSCC. EGFR signaling inhibitors such as EMD 72000, a humanized anti…
Expand
2003
2003
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2003
Corpus ID: 27013008
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE